Morten Harket, lead singer of a-ha, has Parkinson's disease
Morten Harket has revealed he has Parkinson's disease.
The singer of a-ha, the band behind the 1985 hit and innovatively animated music video 'Take On Me,' shared the news during an interview with the group's biographer.
'I've got no problem accepting the diagnosis,' Harket said. 'With time, I've taken to heart my 94-year-old father's attitude to the way the organism gradually surrenders: 'I use whatever works'.'
Harket, 65, explained why he wanted to share his diagnosis publicly.
'Acknowledging the diagnosis wasn't a problem for me; it's my need for peace and quiet to work that has been stopping me. I'm trying the best I can to prevent my entire system from going into decline,' he said. 'It's a difficult balancing act between taking the medication and managing its side effects. There's so much to weigh up when you're emulating the masterful way the body handles every complex movement, or social matters and invitations, or day-to-day life in general.'
According to Mayo Clinic, 'Parkinson's disease is a movement disorder of the nervous system that worsens over time.'
Harket had 'advanced brain surgery' at the Mayo Clinic, which along with medication, 'have softened the impact of his symptoms,' the a-ha biographer, Jan Omdahl, wrote.
'In June 2024, Morten underwent a neurosurgical procedure in which electrodes were implanted deep inside the left side of his brain. These are connected to a small pacemaker-like device placed under the skin of the upper chest that sends electrical impulses through the electrodes into the brain,' Omdahl wrote. 'The method is called deep brain stimulation (DBS) and is among the most advanced treatments in neurology. The procedure had the desired effect: with the right electrical impulses now reaching Morten's brain, many of his physical symptoms practically vanished. In December 2024 he underwent a similar procedure on the right side of his brain, which was also successful.'
Harket's voice, however, has been affected, he said.
'The problems with my voice are one of many grounds for uncertainty about my creative future,' Harket said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vogue
an hour ago
- Vogue
4 Quick And Healthy Breakfasts With 30g Of Protein
If you know you need to eat more protein but aren't sure where to start, breakfast is a good place. Eating a sizeable portion of your daily protein goal first thing not only ticks a box early, it also helps to curb energy slumps, sugar cravings, and sluggishness later in the day. Current guidelines recommend 0.75g of protein per kilogram of body weight per day, but this number can change depending on your age and lifestyle. For example, if you strength train regularly or have an active job, this number may increase. If you're older and more sedentary, it'll decrease. 'Eating a healthy portion of protein for breakfast can help balance blood sugar and energy,' says nutritionist and founder of Artah, Rhian Stephenson, who tends to recommend closer to 1.2g of protein per kilogram of bodyweight to her clients. 'Plus, studies have shown that front-loading your day with adequate protein improves satiety and decreases appetite throughout the day.' Consider us persuaded. Here are four simple high-protein breakfast recipes to incorporate into your morning routine. 1. High-protein yogurt bowl Nutritionist and functional medicine practitioner Farzanah Nasser eats this high-fiber, high-protein breakfast most mornings. 'This recipe hits 30g of protein and 13g of fiber, which is almost half of the daily recommended amount. It also contains two sources of probiotics (which help maintain a healthy gut microbiome), and will keep you full until lunchtime—no energy crashes in sight.' Ingredients 150g 0% fat Greek yogurt ¼ to ½ cup kefir 20g shelled hempseed 20g ground flaxseeds 1 tsp chia seeds 1 heaped tsp oats 1 heaped tsp almond butter Fruit of choice Optional: honey Method Add the yogurt, kefir, hempseed, flaxseeds, chia seeds, and oats into a bowl and mix well. Then top with your fruit of choice (Nasser likes one kiwi fruit) and a drizzle of almond butter and honey. 2. High-protein spinach scramble 'This satisfying breakfast is quick to make and provides a healthy dose of protein to start the day,' says Lingo by Abbott's resident nutritionist, Sophie Bertrand. 'Eggs are rich in a variety of nutrients, including vitamins A, B12, E, as well as choline, zinc, and selenium. The spinach adds beneficial antioxidants and fiber, too.' Ingredients 3 large eggs ¼ cup low-fat cottage cheese ½ cup fresh spinach 1 tsp olive oil Salt and pepper to taste Optional: 1 tbsp chia or hemp seeds Method Heat a pan over medium heat and add the olive oil. Crack the eggs into a bowl and whisk them until the yolks and whites are well combined. Pour the eggs into the pan and cook, stirring gently, until they begin to set but are still slightly runny. Add the cottage cheese and spinach to the eggs and continue cooking, stirring occasionally, until the eggs are fully scrambled and the spinach has wilted. Season with salt and pepper to taste, and sprinkle in chia or hemp seeds if using. Serve immediately and enjoy. 3. High-protein peach smoothie 'This 'springtime in a glass' smoothie not only delivers more than 30g of protein—thanks to the protein powder—but the hemp seeds and nut butter support everything from blood sugar balance to muscle recovery and neurotransmitter health,' says naturopathic nutritionist and hormone specialist Jessica Shand. 'The maca root powder helps with energy and hormone balance, while the bee pollen supports immunity, and the fruit is rich in antioxidants.' Ingredients 200ml organic kefir 50ml unsweetened almond milk 1 scoop protein powder 1 tsp maca powder 1 tbsp bee pollen 1 peach 1 cup frozen raspberries ½ cup frozen avocado ½ cup frozen mango 2 tbsp hemp seed 1 tbsp nut butter Method Add all ingredients to your blender and blitz until smooth. 4. High-protein vegan eggs on toast 'Tofu is a minimally processed product made from soya beans and is an excellent source of protein with good amounts of all nine essential amino acids,' explains plant-based nutritionist Rohini Bajekal. 'This recipe is also rich in herbs and spices, which are the most antioxidant-rich of all food groups. When you use them in dishes, it tends to reduce the desire for excess salt, oil, and sugar.' This recipe pairs well with sourdough or rye bread, says Bajekal, but you could also pop it into a wrap for a portable version. Ingredients 150g firm tofu (15g protein 50g chickpea flour (10g protein) 30g spinach (1g protein) 2 tbsp nutritional yeast (4g protein) 1 slice wholemeal bread (3g protein) ¼ avocado 1 tbsp olive oil ½ small onion, diced ¼ bell pepper, diced ½ tsp turmeric ¼ tsp paprika ¼ tsp cumin Optional: ¼ tsp black salt Salt and pepper to taste Fresh herbs such as basil for garnish Method
Yahoo
3 hours ago
- Yahoo
NHS set for boost of up to £30bn as other budgets feel squeeze
The NHS is expected to receive a funding boost of up to £30 billion in the spending review next week at the expense of other public services. The Department of Health is set to be handed a 2.8% annual increase in its day-to-day budget over a three-year period. The cash injection, which amounts to a rise of about £30 billion by 2028, or £17 billion in real terms, will see other areas including police and councils squeezed, The Times newspaper reported. Sir Keir Starmer has pledged to ensure that by the next election 92% of patients in England waiting for planned treatment are seen within 18 weeks of being referred. Latest NHS data suggests around 60% of people are currently seen in this time and figures released last month showed the overall number of patients on waiting lists had risen slightly from 6.24 million to 6.25 million. Chancellor Rachel Reeves has acknowledged that she had been forced to turn down requests for funding in a sign of the behind-the-scenes wrangling over her spending review. She insisted the blame for the tight economic situation lay with the Conservatives rather than her rigid rules on borrowing and spending. The Chancellor said despite a £190 billion increase in funding over the spending review period 'not every department will get everything that they want next week and I have had to say no to things that I want to do too'. On top of the increase in day-to-day spending, funded in part by the tax hikes Ms Reeves set out in her budget, looser borrowing rules will help support a £113 billion investment package. Economists have warned the Chancellor faces 'unavoidably' tough choices when she sets out departmental spending plans on June 11. The Institute for Fiscal Studies (IFS) think tank said defence and the NHS will dominate the review, raising the prospect of cuts to other unprotected departments.
Yahoo
3 hours ago
- Yahoo
Novo Nordisk Stock: Is It Still a Smart Buy?
This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran pharmaceutical company, however. 10 stocks we like better than Novo Nordisk › Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Novo Nordisk Stock: Is It Still a Smart Buy? was originally published by The Motley Fool
